



CTI Cares Spotlight of the Month

American Brain Tumor Association

nominated by Rachael Gilbert – Biostatistician I

Founded in 1973, the American Brain Tumor Association (ABTA) was the first national nonprofit organization dedicated solely to brain tumors. For 40 years, ABTA has been providing comprehensive resources that support the complex needs of brain tumor patients and caregivers, as well as the critical funding of research in the pursuit of breakthroughs in brain tumor diagnosis, treatment, and care.

[Click here to learn more and donate](#)


Upcoming Meetings CTI will be Attending

...

American College of Cardiology
Washington DC
March 29-31

CTI's Expanded Phase I Capabilities

The addition of Community Research to CTI's full service offerings will be particularly important with the increasing number of early stage clinical trials that pharmaceutical and biotechnology companies are working on. Some of the most groundbreaking research is being done in Phase I units for areas such as rare diseases, regenerative medicine, and oncology. This type of research will only increase in its importance in the next several years.



Community Research, acquired by CTI in January 2014, is a dedicated, multi-specialty clinical research site with three locations throughout Greater Cincinnati, Ohio. Community Research conducts 50-60 Phase I-IV clinical trials annually in a variety of therapeutic indications, including internal medicine, dermatology, psychiatry, and sleep disorders, as well as trials in healthy volunteers. Since its inception nearly 20 years ago, Community Research has completed over 700 clinical trials.

Community Research operates a hospital-based, residential phase I facility, which can accommodate drug and device trials, and has a special emphasis on First-in-Man and early phase studies in various patient populations. This unique location can provide emergency services, on-site clinical laboratory, on-site investigational drug pharmacy, and medical imaging, in addition to their Phase I capabilities.

Usually these studies are designed to examine the safety/tolerability,

**EASL – The International
Liver Congress**
London, UK
April 9-13

Stem Cell Summit
Cambridge, MA
April 23-25

Heart Rhythm Week
Chicago, IL
May 7-10

**Alliance for
Regenerative Medicine
Annual Dinner and
Legislative Fly-in**
Washington DC
May 13-14

If you are interested in
scheduling
a meeting with CTI, please
contact
Nick Schatzman at 513-598-
9290 or at
nschatzman@ctifacts.com

**Welcome the newest
CTI employees:**

**Edward Riestenberg –
Senior Manager, Clinical
Systems**

**Roncarlo Espinola –
Senior Manager, Business
Development, Europe**

**Sandra Comstock – Study
Manager**

**Tanya Botts – Clinical
Safety Scientist II**

Sabine Schoentaube –

pharmacokinetics (PK) and pharmacodynamics (PD) of an investigational drug in human subjects. Community Research has a vast range of experience in Phase I studies, including First-in-Man, SAD-MAD, PK/PD, Drug Interaction, Cardiac Safety Monitoring, Bioequivalence/Bioavailability, Vaccines, Food Effect, Dietary Supplements.

With a focus on clinical research education, Community Research has built a database of over 40,000 healthy subjects and patients. As a result, Community Research has established an excellent track record for recruiting and retaining research participants in Phase 1 studies with traditional and complex designs.

For more information, please contact:

David Mayleben, PhD – Co-Founder and President, Community Research
513.721.3868
dmayleben@communityresearch.com
www.communityresearch.com

Kevin Schwarz – Chief Operating Officer, CTI Clinical Trial and Consulting Services
513.598.9290
kschwarz@ctifacts.com
www.ctifacts.com

About CTI

CTI Clinical Trial and Consulting Services is an innovative, international drug and device development organization that delivers a full spectrum of clinical trial and consulting services from bench to commercialization with a focus on immunology and a passion for helping life-changing therapies succeed in chronically and critically ill patient populations. CTI's focused therapeutic approach provides pharmaceutical, biotechnology and startup firms with clinical and disease area expertise from a unique mix of academic, medical and industry specialists; rich intellectual capital in transplantation, immunology, infectious diseases, hematology, cardiology, nephrology, hepatology, regenerative medicine and rare diseases; flexible study designs that accelerate development programs and deliver high approval ratings that are among the best in the industry; and exceptional global project management and gold standard safety and data management systems that strengthen their program's success potential. Established in 1999 and headquartered in Cincinnati, OH; CTI has offices in North America, Europe and South America.

Administrative Assistant,
Europe

Tyler Meer – Research
Associate

**Congratulations to
these recently
promoted CTI
employees:**

Kelly Solinsky – Senior
Study Manager

Tara Hutchins – Clinical
Data Manager

Kirsten Cooney – Study
Manager

Christie Crosby – Senior
Study Coordinator

**Looking for a job?
CTI is looking for
qualified and
passionate individuals
to fill these positions:**

Clinical Research
Associate – US, Spain, UK,
Germany, Poland,
Australia

Information Technology
Support Specialist –
Europe

Quality Assurance
Auditor – Europe

Senior Director Health
Outcomes Analyst –
Cincinnati, OH

Please visit our website

for complete job
descriptions and to
apply!

Quick Links...

[Website](#)

[Email](#)

Join Our Mailing List!